A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer
Bogang Wu, Win Thant, Elena Bitman…·Leif William Ellisen
This study identifies TROP2 as a regulator of tight junction-mediated immune exclusion in TNBC, showing that targeting TROP2 enhances anti-PD1 therapy response.